

METABOLIC SYNDROME AND PSYCHOTROPIC MEDICATION USE IN VETERANS WITH PTSD (B4), Rita Patel, Noelle Hasson. VA Palo Alto Healthcare System, Palo Alto, CA (rita.patel3@va.gov) IRB approved.

An association between metabolic syndrome and PTSD has been suggested in literature. The objective of this study is to determine the incidence of metabolic syndrome in patients with PTSD. In addition, possible predictors of metabolic syndrome in patients with PTSD will be analyzed, including: atypical antipsychotic use, anticonvulsant use, antidepressant use, hypnotic use, age, and substance abuse. For this retrospective study, medical records of combat veterans admitted to the VAPAHCS 60 day residential milieu PTSD treatment program between January 1, 2004 and December 31, 2008 will be reviewed. To be included in the study, patients must have: (a) stable psychotropic medications for PTSD use for 30 days, (b) a supervised fasting laboratory assessment (HDL, triglyceride, and fasting blood glucose), and (c) a primary diagnosis of PTSD for at least one year as determined by a complete psychiatric interview and the Clinician Administered PTSD Scale. The data was analyzed with Statistical Package for the Social Sciences and Analyses of variance test. Preliminary data on 200 patients has been collected to date. Results and conclusions will be discussed.